JD Health International Inc. (JDHIY) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
JD Health International Inc. (JDHIY) trades at $5.05 with AI Score 49/100 (Grade C). JD Health International Inc. operates an online healthcare platform in China, providing pharmaceutical products and healthcare services. Market cap: $16.2B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 15, 2026Analyst Coverage for JDHIY: JDHIY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates JDHIY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
JDHIY: this read rests on a single discipline (MoonshotScore) — the other council disciplines have no scored data yet.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
JD Health International Inc. (JDHIY) Healthcare & Pipeline Overview
JD Health International Inc. (JDHIY) is a leading online healthcare platform in China, offering pharmaceutical products, online healthcare services, and health management solutions. Leveraging its parent company JD.com's e-commerce infrastructure, JD Health provides convenient access to healthcare for a large customer base in a rapidly growing digital health market.
What Is the Investment Thesis for JDHIY?
JD Health International Inc. presents a notable research candidate within China's rapidly expanding digital healthcare market. With a market capitalization of $16.2B and a P/E ratio of 25.98, the company demonstrates significant market presence and profitability, indicated by a 7.3% profit margin. Key value drivers include the increasing adoption of online healthcare services in China, driven by convenience and accessibility. Growth catalysts involve expanding service offerings, penetrating lower-tier cities, and leveraging AI-driven healthcare solutions. However, potential risks include regulatory uncertainties in the Chinese healthcare sector and competition from established players. The company's beta of 1.16 suggests a slightly higher volatility compared to the market.
Based on FMP financials and quantitative analysis
JDHIY Key Highlights
Market capitalization of $16.2B, reflecting a substantial market valuation.
- P/E ratio of 25.98, indicating investor expectations of future earnings growth.
- Profit margin of 7.3%, showcasing the company's ability to generate profit from its revenue.
- Gross margin of 24.8%, highlighting the efficiency of its supply chain and pricing strategies.
- Employs 3564 individuals, demonstrating a significant operational scale.
Who Are JDHIY's Competitors?
JDHIY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ANHGY Mediclinic International plc | $5.49 | +0.00% | $4.05B | 44 |
| COLRF China Medical & HealthCare Group Limited | $0.08 | +0.00% | $80.8M | 48 |
| ESALY Eisai Co., Ltd. | $61.51 | -2.11% | $17.6B | 57 |
| IHHHF IHH Healthcare Berhad | $1.71 | +0.00% | $15.1B | 51 |
| SOLV Solventum Corporation | $88.98 | +1.33% | $15.4B | 56 |
| EHC Encompass Health Corporation | $120.91 | -0.68% | $12.0B | 88 |
| THC Tenet Healthcare Corporation | $274.81 | +2.34% | $22.1B | 86 |
| DVA DaVita Inc. | $177.27 | -0.36% | $11.4B | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are JDHIY's Key Strengths?
Strong brand recognition and trust in China.
- Integration with JD.com's extensive e-commerce infrastructure.
- Comprehensive range of pharmaceutical products and healthcare services.
- Large and growing user base.
What Are JDHIY's Weaknesses?
Reliance on regulatory approvals in the Chinese healthcare sector.
- Competition from established players in the online healthcare market.
- Potential for data security and privacy breaches.
- Limited international presence.
What Could Drive JDHIY Stock Higher?
Expansion of online healthcare services to new therapeutic areas.
- Increasing adoption of telehealth and remote patient monitoring in China.
- Potential regulatory approvals for new pharmaceutical products.
- Strategic partnerships with hospitals and healthcare providers.
- Growth in the aging population and increasing demand for healthcare services.
What Are the Key Risks for JDHIY?
Regulatory changes in the Chinese healthcare sector.
- Increasing competition from established players in the online healthcare market.
- Cybersecurity threats and data breaches.
- Economic slowdown in China.
- Currency fluctuations affecting the value of ADRs.
What Are the Growth Opportunities for JDHIY?
- Expanding Online Healthcare Services: JD Health can further capitalize on the growing demand for online healthcare services in China. By expanding its offerings to include chronic disease management, mental health support, and specialized consultations, the company can attract a larger user base. The market for online healthcare services in China is projected to reach $50 billion by 2028, presenting a significant growth opportunity for JD Health.
- Penetrating Lower-Tier Cities: JD Health has the opportunity to expand its reach into lower-tier cities and rural areas in China, where access to quality healthcare is limited. By leveraging its online platform and logistics network, the company can provide convenient and affordable healthcare solutions to underserved populations. This expansion strategy could unlock a new market segment of over 500 million potential customers.
- Leveraging AI-Driven Healthcare Solutions: JD Health can leverage artificial intelligence (AI) to enhance its healthcare services and improve patient outcomes. By developing AI-powered diagnostic tools, personalized treatment plans, and virtual assistants, the company can differentiate itself from competitors and attract tech-savvy consumers. The AI in healthcare market is expected to reach $34 billion by 2027, offering a substantial growth avenue.
- Strengthening Partnerships with Hospitals and Doctors: JD Health can strengthen its partnerships with hospitals and doctors to expand its service offerings and improve the quality of care. By collaborating with leading medical institutions, the company can provide access to specialized consultations, remote monitoring, and post-discharge care. These partnerships can enhance JD Health's credibility and attract more patients to its platform.
- Expanding Pharmaceutical Product Portfolio: JD Health can expand its pharmaceutical product portfolio to include a wider range of prescription drugs, over-the-counter medications, and health supplements. By offering a comprehensive selection of products, the company can become a one-stop shop for healthcare needs and increase customer loyalty.
What Are JDHIY's Competitive Advantages?
- Integration with JD.com's e-commerce platform, providing access to a large customer base.
- Extensive online retail pharmacy network, ensuring convenient access to medications.
- Comprehensive range of healthcare services, creating a one-stop shop for healthcare needs.
- Strong brand reputation and trust among consumers in China.
- Data analytics capabilities, enabling personalized healthcare recommendations and services.
What Does JDHIY Do?
JD Health International Inc., established in 2018 and headquartered in Beijing, is an investment holding company operating a comprehensive online healthcare platform in the People's Republic of China. As a subsidiary of JD Jiankang Limited, JD Health leverages the robust e-commerce infrastructure of its parent company, JD.com, to provide a wide array of pharmaceutical and healthcare products and services. The company's offerings include over-the-counter (OTC) drugs, prescription drugs, medical devices and supplies, as well as health supplements and tonics, distributed through direct sales and an extensive online retail pharmacy network. Beyond product sales, JD Health delivers online healthcare services such as online consultations, hospital or doctor referrals, health check-ups, genetic testing, and beauty care services. It also provides health management and intelligent healthcare solutions, alongside technical and advertising services. Furthermore, JD Health facilitates access to medical checkups, medical aesthetics, vaccination appointments, dental care services, and nucleic acid testing. The company's integrated approach aims to enhance healthcare accessibility and convenience for consumers across China.
What Products and Services Does JDHIY Offer?
- Operates an online healthcare platform in China.
- Offers pharmaceutical products, including OTC and prescription drugs.
- Provides medical devices and supplies.
- Sells health supplements and tonics.
- Offers online healthcare services like consultations and referrals.
- Provides health management and intelligent healthcare solutions.
- Offers access to medical checkups and other healthcare appointments.
How Does JDHIY Make Money?
- Direct sales of pharmaceutical and healthcare products through its online platform.
- Online retail pharmacy network for prescription and OTC drugs.
- Service fees from online healthcare services, such as consultations and referrals.
- Revenue from health management and intelligent healthcare solutions.
- Technical and advertising services for healthcare providers.
What Industry Does JDHIY Operate In?
JD Health operates within China's burgeoning digital healthcare market, which is experiencing rapid growth due to increasing internet penetration, rising healthcare costs, and government support for online healthcare initiatives. The competitive landscape includes companies like ANHGY (Anthemis Group), COLRF (CloudMD Software & Services Inc), ESALY (EssilorLuxottica SA), IHHHF (IHH Healthcare Bhd), and NMHLY (NMHLY). JD Health differentiates itself through its integration with JD.com's e-commerce platform, providing a seamless user experience and access to a vast customer base. The industry is characterized by evolving regulations and increasing demand for personalized and convenient healthcare solutions.
Who Are JDHIY's Key Customers?
- Individual consumers seeking pharmaceutical products and healthcare services.
- Patients requiring online consultations and referrals to specialists.
- Individuals seeking health check-ups and other preventative care services.
- Hospitals and doctors utilizing JD Health's platform for patient management.
- Corporations seeking health management solutions for their employees.
Forward Outlook
Wall Street analysts project JD Health International Inc. revenue of about $85.92B for fiscal 2026, with EPS near $0.00. The estimate reflects 16 contributing analysts.
Financial Health
JD Health International Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 5.38 places it in the safe zone, indicating low near-term bankruptcy risk.
Key Financial Metrics
Return on equity for JD Health International Inc. stands at 9.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 6.6%, showing how much profit it generates from its asset base. JDHIY trades at a trailing price-to-earnings ratio of 16.89, below the Healthcare sector average of ~23x. Its free cash flow yield is 11.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.72 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.9%, the inverse of the P/E and a quick read on earnings relative to price.
JD Health International Inc. (JDHIY) Valuation Context
Valued at $16.2B, JDHIY is classified as a large-cap stock. Relative to its peer group, JDHIY's quantitative score of 49/100 is roughly in line with the peer average of 51/100.
JDHIY Revenue & Earnings Trend
In Q2 2026, JDHIY generated $40.44B in top-line revenue, marking a sequential increase of 8.0%. The company recorded net income of $3.40B, with diluted EPS of $1.09. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this large-cap Healthcare company. Across the four most recent quarters, JDHIY averaged $0.85 in diluted EPS.
Company Profile
JD Health International Inc. operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Beijing, CN. The company is led by CEO Cao Dong. JDHIY has traded publicly since 2022.
JDHIY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Strong brand recognition and trust in China.
- Integration with JD.com's extensive e-commerce infrastructure.
- Comprehensive range of pharmaceutical products and healthcare services.
- Large and growing user base.
Bear Case
- Reliance on regulatory approvals in the Chinese healthcare sector.
- Competition from established players in the online healthcare market.
- Potential for data security and privacy breaches.
- Limited international presence.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $40.44B | $3.40B | $1.09 |
| Q4 2025 | $37.45B | $2.73B | $0.84 |
| Q2 2025 | $35.29B | $2.60B | $0.81 |
| Q4 2024 | $29.82B | $2.12B | $0.67 |
Based on FMP financials and quantitative analysis
JDHIY Latest News
No recent news available for JDHIY.
JDHIY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for JDHIY.
Price Targets
Wall Street price target analysis for JDHIY.
JDHIY MoonshotScore
What does this score mean?
The MoonshotScore rates JDHIY 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Cao Dong
CEO
Cao Dong serves as the CEO of JD Health International Inc., overseeing the company's strategic direction and operations. His background includes extensive experience in the healthcare and technology sectors. Prior to joining JD Health, Cao Dong held leadership positions at various healthcare companies, where he focused on digital transformation and innovation. He holds a degree in Business Administration and has completed executive education programs at leading business schools.
Track Record: Under Cao Dong's leadership, JD Health has experienced significant growth and expansion. He has spearheaded the company's efforts to develop innovative healthcare solutions and strengthen its partnerships with hospitals and doctors. Cao Dong has also played a key role in driving JD Health's expansion into lower-tier cities and rural areas in China. His strategic decisions have contributed to the company's strong market position and financial performance.
JD Health International Inc. ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. JDHIY is an ADR that allows U.S. investors to invest in JD Health International Inc. without directly dealing with the Chinese stock market. Each JDHIY ADR represents a specific number of JD Health shares traded on its home market.
- Home Market Ticker: Hong Kong Stock Exchange (JDHI)
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: JDHI
JDHIY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies trading on this tier typically have limited reporting requirements and may not meet the listing standards of major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the lack of regulatory oversight and transparency compared to listed companies.
- OTC Tier: OTC Other
- Limited regulatory oversight and transparency.
- Potential for price volatility and illiquidity.
- Higher risk of fraud or manipulation.
- Limited availability of financial information.
- Potential for delisting or trading suspension.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the company's management team and track record.
- Check for any regulatory actions or legal proceedings.
- Monitor trading volume and bid-ask spreads.
- Consult with a financial advisor before investing.
- Association with JD.com, a reputable e-commerce company.
- Operation of an online healthcare platform in China.
- Provision of pharmaceutical products and healthcare services.
- Presence in the healthcare sector.
- Employing over 3500 employees.
Common Questions About JDHIY (Healthcare)
What does the AI Score mean for JDHIY?
JDHIY holds an AI Score of 49/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. JD Health International Inc. operates an online healthcare platform in China, providing pharmaceutical products and healthcare services. The company leverages its online retail pharmacy network …
What does JD Health International Inc. do?
JD Health International Inc. operates as a comprehensive online healthcare platform in China, offering a wide range of pharmaceutical products, including prescription and over-the-counter medications, as well as medical devices and health supplements. Beyond product sales, the company provides online healthcare services such as virtual consultations, hospital referrals, and health check-up bookings.
What are the main risks for JDHIY?
The main risks for JDHIY include regulatory changes in the Chinese healthcare sector, which could impact the company's operations and profitability. Increasing competition from both domestic and international players in the online healthcare market poses a threat to JD Health's market share. Cybersecurity threats and data breaches could compromise patient data and damage the company's reputation. Additionally, economic slowdown in China and currency fluctuations could negatively affect JDHIY's financial performance.
What are the key factors to evaluate for JDHIY?
JD Health International Inc. (JDHIY) holds an AI score of 49/100 (low). presents a notable research candidate within China's rapidly expanding digital healthcare market. Not financial advice.
How frequently does JDHIY data refresh on this page?
JDHIY's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven JDHIY's recent stock price performance?
JD Health International Inc. (JDHIY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong brand recognition and trust in China. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider JDHIY overvalued or undervalued right now?
JD Health International Inc. (JDHIY) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research JDHIY before investing?
Before investing in JD Health International Inc. (JDHIY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding JDHIY to a portfolio?
Key strength of JD Health International Inc. (JDHIY): Strong brand recognition and trust in China. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for JDHIY, limiting comprehensive insights.
- OTC market carries inherent risks due to lower transparency.